Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2008

Oncolytics Transfers 40 L cGMP Manufacturing Process for Anticancer Agent to SAFC Pharma

  • Oncolytics Biotech reports successfully transferred cGMP production for its cancer drug candidate at the 40-liter batch size to SAFC Pharma. The compound Reolysin is in multiple clinical programs in different cancer types.

    Yields at the 40-litre scale should provide sufficient doses to support future development plans leading to registration and the anticipated early-stage commercial requirements, notes Oncolytics. Development work to support further scale-up to the 100-litre level is currently under way.

    “Consistent with our previous announcement of a $12 million expansion of capacity, we will be in a position to support commercial production of Reolysin,” says Jeffrey L. Strobel, Ph.D., site director at SAFC Pharma’s operation in Carlsbad, CA. The Carlsbad facility supports the viral vector and vaccine community with its process development and analytical laboratory expertise as well as its cGMP capability, he adds.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »